Maze Therapeutics (NASDAQ:MAZE) Receives Buy Rating from HC Wainwright

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $110.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 305.10% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Citigroup initiated coverage on shares of Maze Therapeutics in a research report on Wednesday. They set a “buy” rating and a $50.00 target price for the company. BTIG Research reiterated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday. Wedbush reiterated an “outperform” rating and set a $48.00 price objective on shares of Maze Therapeutics in a research report on Wednesday. Finally, TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $63.40.

Maze Therapeutics Price Performance

MAZE stock traded down $0.94 during midday trading on Thursday, hitting $27.15. 243,285 shares of the stock were exchanged, compared to its average volume of 659,404. The stock’s 50-day moving average price is $27.18 and its 200-day moving average price is $29.17. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -10.76 and a beta of 2.17. Maze Therapeutics has a fifty-two week low of $21.95 and a fifty-two week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.76). Research analysts predict that Maze Therapeutics will post -2.72 earnings per share for the current year.

Insiders Place Their Bets

In other Maze Therapeutics news, CEO Jason Coloma sold 11,411 shares of Maze Therapeutics stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total value of $296,800.11. Following the completion of the sale, the chief executive officer owned 27,362 shares in the company, valued at $711,685.62. The trade was a 29.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Atul Dandekar sold 3,243 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $84,350.43. Following the completion of the sale, the insider owned 32,316 shares of the company’s stock, valued at approximately $840,539.16. The trade was a 9.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 191,459 shares of company stock valued at $5,263,539 in the last quarter. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Royal Bank of Canada increased its holdings in Maze Therapeutics by 214.1% in the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after purchasing an additional 1,383 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Maze Therapeutics during the second quarter worth about $48,000. Quantbot Technologies LP purchased a new stake in shares of Maze Therapeutics in the second quarter worth about $80,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Maze Therapeutics in the fourth quarter valued at about $145,000. Finally, IFP Advisors Inc acquired a new stake in shares of Maze Therapeutics in the fourth quarter valued at about $146,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.